Immunogenicity and safety of a heterologous prime-boost COVID-19 vaccine schedule: ChAdOx1 vaccine Covishield followed by BBV152 Covaxin-Reference-Cited by-同舟云学术

Immunogenicity and safety of a heterologous prime-boost COVID-19 vaccine schedule: ChAdOx1 vaccine Covishield followed by BBV152 Covaxin

Published:2021-10-15 Issue:8 Volume:28 Page:
ISSN:1195-1982
Container-title:Journal of Travel Medicine
language:en
Short-container-title:

Author:

Kant Rajni¹,Dwivedi Gaurav¹,Zaman Kamran¹,Sahay Rima R²,Sapkal Gajanan²,Kaushal Himanshu²,Nyayanit Dimpal A²,Yadav Pragya D²^ORCID,Deshpande Gururaj²,Singh Rajeev¹,Chaowdhary Sandeep³,Gupta Nivedita⁴,Kumar Sanjay⁵,Abraham Priya²,Panda Samiran⁴^ORCID,Bhargava Balram⁴

Affiliation:

1. Indian Council of Medical Research-Regional Medical Research Centre (RMRC), Gorakhpur, Uttar Pradesh, 273013, India

2. Indian Council of Medical Research-National Institute of Virology (ICMR-NIV), Pune, Maharashtra, 411021, India

3. Chief Medical Officer, Community Health Centre, Siddarthnagar, Uttar Pradesh, 272207, India

4. Indian Council of Medical Research, V. Ramalingaswami Bhawan, P.O. Box No. 4911, Ansari Nagar, New Delhi, 110029, India

5. Command Hospital (Southern Command), Armed Forces Medical College, Pune, Maharashtra, 411040, India

Abstract

The evidence for effectiveness of heterologous priming of COVID-19 vaccine is very limited. Here, we studied eighteen participants who received heterologous vaccination regimen of AstraZeneca’s ChAdOx1-nCov-19 followed by inactivated whole virion BBV152. Heterologous group participant doesn’t report any adverse event following immunization and demonstrated high humoral and neutralizing antibody response.

Publisher

Oxford University Press (OUP)

Subject

General Medicine

Link

https://academic.oup.com/jtm/advance-article-pdf/doi/10.1093/jtm/taab166/41092277/taab166.pdf

Reference5 articles.

1. Full-genome sequences of the first two SARS-CoV-2 viruses from India;Yadav;Indian J Med Res,2020

2. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial;Ella;Lancet Infect Dis,2021

3. Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial;Ella;Lancet Infect Dis,2021

4. Efficacy, safety, and lot to lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): a, double-blind, randomised, controlled phase 3 trial

5. India’s role in COVID-19 vaccine diplomacy;Sharun;J Travel Med,2021

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The impact of Omicron on the COVID-19 vaccines: A review;Vacunas (English Edition);2024-04

2. The impact of Omicron on the COVID-19 vaccines: A review;Vacunas;2024-04

3. Short-term SARS-CoV-2 Re-infection Rate in Vaccinated Health Workers based on Received Vaccines: A Cross-sectional Study;Current Respiratory Medicine Reviews;2023-11

4. Heterologous vaccination with subunit protein vaccine induces a superior neutralizing capacity against BA.4/5‐included SARS‐CoV‐2 variants than homologous vaccination of mRNA vaccine;MedComm;2023-03-10

5. Safety and efficacy of COVID-19 prime-boost vaccinations: Homologous BBIBP-CorV versus heterologous BNT162b2 boosters in BBIBP-CorV-primed individuals;Vaccine;2023-03